The first modern, patient-wearable TENS was patented in the United States in 1974. It was initially used for testing the tolerance of chronic pain patients to electrical stimulation before implantation of electrodes in the spinal cord dorsal column. The electrodes were attached to an implanted receiver, which received its power from an antenna worn on the surface of the skin. Although intended only for testing tolerance to electrical stimulation, many of the patients said they received so much relief from the TENS itself that they never returned for the implant.
A number of companies began manufacturing TENS units after the commercial success of the Medtronic device became known. The neurological division of Medtronic, founded by Don Maurer, Ed Schuck and Dr. Charles Ray, developed a number of applications for implanted electrical stimulation devices for treatment of epilepsy, Parkinson's disease, and other disorders of the nervous system. Maurer founded Empi, Inc., in 1977, and in the late 1980s purchased the TENS product line from Medtronic.
Today many people confuse TENS with Electro Muscle Stimulation (EMS). EMS and TENS devices look similar, with both using long electric lead wires and electrodes. TENS is for blocking pain, where EMS is for stimulating muscles.
TENS is a non-invasive, safe nerve stimulation intended to reduce pain, both acute and chronic. While controversy exists as to its effectiveness in the treatment of chronic pain, a number of systematic reviews or meta-analyses have confirmed its effectiveness for postoperative pain, osteoarthritis, and chronic musculoskeletal pain. Conversely, results from the Bone and Joint Decade 2000-2010 Task Force on Neck Pain, reported in early 2008, showed no clinically significant benefit to TENS for the treatment of neck pain when compared to sham treatment. A January 2010, systematic literature search published in the journal Neurology, advised against recommending TENS for chronic low back pain since evidence is controversial for that type of pain. However, other reputable neurologists wrote in the same issue of the journal: "Absence of evidence is not evidence of absence," and although the research on TENS may be thin, "there seems to be considerable empirical evidence that, at least in some patients, TENS is useful." Recent clinical studies and meta-analysis suggest that having an adequate intensity of stimulation is necessary to achieve pain relief with TENS.
Scientific studies show that high and low frequency TENS produce their effects by activation of opioid receptors in the central nervous system. Specifically, high frequency TENS activates delta-opioid receptors both in the spinal cord and supraspinally (in the medulla) while low frequency TENS activates beta-opioid receptors both in the spinal cord and supraspinally. Further high frequency TENS reduces excitation of central neurons that transmit nociceptive information, reduces release of excitatory neurotransmitters (glutamate) and increases the release of inhibitory neurotransmitters (GABA) in the spinal cord, and activates muscarinic receptors centrally to produce analgesia (in effect, temporarily blocking the pain gate). Low frequency TENS also releases serotonin and activates serotonin receptors in the spinal cord, releases GABA, and activates muscarinic receptors to reduce excitability of nociceptive neurons in the spinal cord.
In palliative care and pain medicine, TENS units are used in an attempt to temporarily alleviate neuropathic pain (pain due to nerve damage). Some patients benefit from this approach, while others do not, depending on individual differences, and pain threshold. Use of TENS causes cell death at the site of application and should not be used long term. The number of cells that die is insignificant and most patients heal without complaints. TENS is more effective at relieving chronic pain, whereas when used on new injuries it sometimes aggravates the pain. Further use is documented in the attached references: in obstetric care, particularly in labour; knee pain; lithotripsy or bladder-stone removal; and limb pain.
A significant number of TENS machine brands have been targeted for use for labour pain, although a 1997 report of a study done by the University of Oxford said that TENS "has been shown not to be effective in postoperative and labour pain."
Over the eyes due to the risk of increasing intraocular pressure Transcerebrally On the front of the neck due to the risk of a acute hypotension (through a vasovagal reflex) or even a laryngospasm Through the chest using an anterior and posterior electrode positions, or other transthoracic applications understood as "across a thoracic diameter"; this does not preclude coplanar applications Internally, except for specific applications of dental, vaginal, and anal stimulation that employ specialized TENS units On broken skin areas or wounds, although it can be placed around wounds. Over a tumour/malignancy (based on in vitro experiments where electricity promotes cell growth)
TENS should not be used across an artificial cardiac pacemaker (or other indwelling stimulator, including across its leads) due to risk of interference and failure of the implanted device. Serious accidents have been recorded in cases when this principle was not observed. A 2009 review in this area suggests that eletrotherapy, including TENS, "are best avoided" in patients with pacemakers or implantable cardioverter-defibrillators (ICDs). They add that "there is no consensus and it may be possible to safely deliver these modalities in a proper setting with device and patient monitoring", and recommend further research. The review found several reports of ICDs administering inappropriate treatment due to interference with TENS devices, but notes that the reports on pacemakers are mixed: some non-programmable pacemakers were inhibited by TENS, but others were unaffected or auto-reprogrammed.
On areas of numb skin/decreased sensation TENS should be used with caution because it's likely less effective due to nerve damage. It may also cause skin irritation due to the inability to feel currents until they are too high. There's an unknown level of risk when placing electrodes over an infection (possible spreading due to muscle contractions), but cross contamination with the electrodes themselves is of greater concern. TENS should also be used with caution in people with epilepsy or pregnant women; do not use over area of the uterus as the effects of electrical stimulation over the developing fetus are not known.
Category:Medical equipment Category:Pain Category:Neurotechnology Category:Electrotherapy
ca:TENS de:Transkutane elektrische Nervenstimulation it:TENS ja:経皮的末梢神経電気刺激 pl:Przezskórna stymulacja nerwów pt:TENS ru:Миостимулятор simple:Transcutaneous Electrical Nerve Stimulator fi:TNS-hoito sv:TENSThis text is licensed under the Creative Commons CC-BY-SA License. This text was originally published on Wikipedia and was developed by the Wikipedia community.
The World News (WN) Network, has created this privacy statement in order to demonstrate our firm commitment to user privacy. The following discloses our information gathering and dissemination practices for wn.com, as well as e-mail newsletters.
We do not collect personally identifiable information about you, except when you provide it to us. For example, if you submit an inquiry to us or sign up for our newsletter, you may be asked to provide certain information such as your contact details (name, e-mail address, mailing address, etc.).
When you submit your personally identifiable information through wn.com, you are giving your consent to the collection, use and disclosure of your personal information as set forth in this Privacy Policy. If you would prefer that we not collect any personally identifiable information from you, please do not provide us with any such information. We will not sell or rent your personally identifiable information to third parties without your consent, except as otherwise disclosed in this Privacy Policy.
Except as otherwise disclosed in this Privacy Policy, we will use the information you provide us only for the purpose of responding to your inquiry or in connection with the service for which you provided such information. We may forward your contact information and inquiry to our affiliates and other divisions of our company that we feel can best address your inquiry or provide you with the requested service. We may also use the information you provide in aggregate form for internal business purposes, such as generating statistics and developing marketing plans. We may share or transfer such non-personally identifiable information with or to our affiliates, licensees, agents and partners.
We may retain other companies and individuals to perform functions on our behalf. Such third parties may be provided with access to personally identifiable information needed to perform their functions, but may not use such information for any other purpose.
In addition, we may disclose any information, including personally identifiable information, we deem necessary, in our sole discretion, to comply with any applicable law, regulation, legal proceeding or governmental request.
We do not want you to receive unwanted e-mail from us. We try to make it easy to opt-out of any service you have asked to receive. If you sign-up to our e-mail newsletters we do not sell, exchange or give your e-mail address to a third party.
E-mail addresses are collected via the wn.com web site. Users have to physically opt-in to receive the wn.com newsletter and a verification e-mail is sent. wn.com is clearly and conspicuously named at the point of
collection.If you no longer wish to receive our newsletter and promotional communications, you may opt-out of receiving them by following the instructions included in each newsletter or communication or by e-mailing us at michaelw(at)wn.com
The security of your personal information is important to us. We follow generally accepted industry standards to protect the personal information submitted to us, both during registration and once we receive it. No method of transmission over the Internet, or method of electronic storage, is 100 percent secure, however. Therefore, though we strive to use commercially acceptable means to protect your personal information, we cannot guarantee its absolute security.
If we decide to change our e-mail practices, we will post those changes to this privacy statement, the homepage, and other places we think appropriate so that you are aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it.
If we make material changes to our e-mail practices, we will notify you here, by e-mail, and by means of a notice on our home page.
The advertising banners and other forms of advertising appearing on this Web site are sometimes delivered to you, on our behalf, by a third party. In the course of serving advertisements to this site, the third party may place or recognize a unique cookie on your browser. For more information on cookies, you can visit www.cookiecentral.com.
As we continue to develop our business, we might sell certain aspects of our entities or assets. In such transactions, user information, including personally identifiable information, generally is one of the transferred business assets, and by submitting your personal information on Wn.com you agree that your data may be transferred to such parties in these circumstances.